‌

US Patent 11999802 Compositions and methods for selective protein degradation

Patent 11999802 was granted and assigned to Novartis on June, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jonathan M. Solomon0

James E. Bradner0

Seth Carbonneau0

Marc Horst Peter Hild0

Nathan Thomas Ross0

Carleton Proctor Goold0

Rohan Eric John Beckwith0

Carla Patricia Pinto Guimaraes0

...

Date of Patent

June 4, 2024

0

Patent Application Number

167570260

Date Filed

October 18, 2018

0

Patent Citations

US Patent 7320787 Redirection of cellular immunity by protein tyrosine kinase chimeras

0

US Patent 7049136 Redirection of cellular immunity by receptor chimeras

0

US Patent 7052906 Synthetic transmembrane components

0

US Patent 7070995 CE7-specific redirected immune cells

0

US Patent 7265209 CE7-specific chimeric T cell receptor

0

US Patent 7319143 Genetically-engineered MHC molecules

0

US Patent 8911993 Compositions for treatment of cancer

0

US Patent 8916381 Methods for treatment of cancer

0

...

Patent Primary Examiner

0

Patent abstract

The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a COF1/CRBN-binding polypeptide, COF2/CRBN-binding polypeptide, or COF3/CRBN-binding polypeptide and a heterologous polypeptide of interest.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11999802 Compositions and methods for selective protein degradation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.